Abstract
Therapeutic strategies for neurological disorders are now spreading in many directions. Previously, the removal of regeneration-inhibitory environments in the brain, together with the introduction of regeneration-promotive characteristics of the peripheral nerves has been explored. More recently, the effect of transplantation of stem cell-derived cells on traumatic injury and neurodegenerative disorders has been examined. Among various approaches aimed at a recovery from neurodegeneration, neuronal protection based on the understanding of degeneration mechanisms is an attractive alternative, especially for neurodegenerative disorders.
Axon degeneration is a hallmark of many neurological disorders, including neuropathies and neurodegenerative diseases. Previous studies have shown that subcellular signaling which promotes axonal degeneration is independent from the typical cell death signal. Whereas, axonal protection mechanism, as shown in a naturally occurring mutant strain wallerian degeneration slow (wlds) mice, can save both axons and cell bodies from some types of insults, but the existence of common regulatory mechanism(s) between Wallerian degeneration and neuronal apoptosis remains to be fully elucidated. In this chapter, we introduce a general overview of both well-established and newly discovered pathways that control the progression of Wallerian degeneration, and we also describe how E3 ubiquitin ligase zinc and ring finger 1 (ZNRF1) functions as a critical mediator for neurodegenerative pathways, Wallerian degeneration and neuronal apoptosis, by translating oxidative stress into subcellular signaling in neurons. Our results presented here, suggest that the pathophysiological significance of ZNRF1-mediated signaling in the regulation of both Wallerian degeneration and neuronal apoptosis is a potential therapeutic avenue against neurodegenerative disorders.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Aguayo AJ, David S, Bray GM (1981) Influences of the glial environment on the elongation of axons after injury: transplantation studies in adult rodents. J Exp Biol 95:231–240
Araki T, Milbrandt J (2003) ZNRF proteins constitute a family of presynaptic E3 ubiquitin ligases. J Neurosci 23:9385–9394
Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010–1013
Araujo IM, Carvalho CM (2005) Role of nitric oxide and calpain activation in neuronal death and survival. Curr Drug Targets CNS Neurol Disord 4:319–324
Babetto E, Beirowski B, Janeckova L, Brown R, Gilley J, Thomson D, Ribchester RR, Coleman MP (2010) Targeting NMNAT1 to axons and synapses transforms its neuroprotective potency in vivo. J Neurosci 30:13291–13304
Babetto E, Beirowski B, Russler EV, Milbrandt J, DiAntonio A (2013) The Phr1 ubiquitin ligase promotes injury-induced axon self-destruction. Cell Rep 3:1422–1429
Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, Nicotera P (2005) Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell 120:275–285
Berger F, Lau C, Dahlmann M, Ziegler M (2005) Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. J Biol Chem 280:36334–36341
Blandini F, Armentero MT (2012) Animal models of Parkinson’s disease. FEBS J 279:1156–1166
Bloom AJ, Miller BR, Sanes JR, DiAntonio A (2007) The requirement for Phr1 in CNS axon tract formation reveals the corticostriatal boundary as a choice point for cortical axons. Genes Dev 21:2593–2606
Brichta L, Greengard P, Flajolet M (2013) Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. Trends Neurosci 36:543–554
Brosius Lutz A, Barres BA (2014) Contrasting the glial response to axon injury in the central and peripheral nervous systems. Dev Cell 28:7–17
Broughton BR, Reutens DC, Sobey CG (2009) Apoptotic mechanisms after cerebral ischemia. Stroke J Cereb Circul 40:e331–e339
Camins A, Verdaguer E, Folch J, Pallas M (2006) Involvement of calpain activation in neurodegenerative processes. CNS Drug Rev 12:135–148
Chen ZL, Yu WM, Strickland S (2007) Peripheral regeneration. Annu Rev Neurosci 30:209–233
Chen CY, Lin CW, Chang CY, Jiang ST, Hsueh YP (2011) Sarm1, a negative regulator of innate immunity, interacts with syndecan-2 and regulates neuronal morphology. J Cell Biol 193:769–784
Cheng HC, Burke RE (2010) The Wld(S) mutation delays anterograde, but not retrograde, axonal degeneration of the dopaminergic nigro-striatal pathway in vivo. J Neurochem 113:683–691
Cheng HC, Kim SR, Oo TF, Kareva T, Yarygina O, Rzhetskaya M, Wang C, During M, Talloczy Z, Tanaka K, Komatsu M, Kobayashi K, Okano H, Kholodilov N, Burke RE (2011) Akt suppresses retrograde degeneration of dopaminergic axons by inhibition of macroautophagy. J Neurosci 31:2125–2135
Chuang CF, Bargmann CI (2005) A Toll-interleukin 1 repeat protein at the synapse specifies asymmetric odorant receptor expression via ASK1 MAPKKK signaling. Genes Dev 19:270–281
Cole AR, Noble W, van Aalten L, Plattner F, Meimaridou R, Hogan D, Taylor M, LaFrancois J, Gunn-Moore F, Verkhratsky A, Oddo S, LaFerla F, Giese KP, Dineley KT, Duff K, Richardson JC, Yan SD, Hanger DP, Allan SM, Sutherland C (2007) Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer’s disease progression. J Neurochem 103:1132–1144
Coleman M (2005) Axon degeneration mechanisms: commonality amid diversity. Nat Rev Neurosci 6:889–898
Coleman MP, Freeman MR (2010) Wallerian degeneration, wld(s), and nmnat. Annu Rev Neurosci 33:245–267
Coleman MP, Conforti L, Buckmaster EA, Tarlton A, Ewing RM, Brown MC, Lyon MF, Perry VH (1998) An 85-kb tandem triplication in the slow Wallerian degeneration (Wlds) mouse. Proc Natl Acad Sci U S A 95:9985–9990
Conforti L, Tarlton A, Mack TG, Mi W, Buckmaster EA, Wagner D, Perry VH, Coleman MP (2000) A Ufd2/D4Cole1e chimeric protein and overexpression of Rbp7 in the slow Wallerian degeneration (WldS) mouse. Proc Natl Acad Sci U S A 97:11377–11382
Conforti L, Gilley J, Coleman MP (2014) Wallerian degeneration: an emerging axon death pathway linking injury and disease. Nat Rev Neurosci 15:394–409
Crocker SJ, Smith PD, Jackson-Lewis V, Lamba WR, Hayley SP, Grimm E, Callaghan SM, Slack RS, Melloni E, Przedborski S, Robertson GS, Anisman H, Merali Z, Park DS (2003) Inhibition of calpains prevents neuronal and behavioral deficits in an MPTP mouse model of Parkinson’s disease. J Neurosci 23:4081–4091
D’Orsi B, Bonner H, Tuffy LP, Dussmann H, Woods I, Courtney MJ, Ward MW, Prehn JH (2012) Calpains are downstream effectors of bax-dependent excitotoxic apoptosis. J Neurosci 32:1847–1858
Fang Y, Bonini NM (2012) Axon degeneration and regeneration: insights from Drosophila models of nerve injury. Annu Rev Cell Dev Biol 28:575–597
Ferri A, Sanes JR, Coleman MP, Cunningham JM, Kato AC (2003) Inhibiting axon degeneration and synapse loss attenuates apoptosis and disease progression in a mouse model of motoneuron disease. Curr Biol 13:669–673
Finn JT, Weil M, Archer F, Siman R, Srinivasan A, Raff MC (2000) Evidence that Wallerian degeneration and localized axon degeneration induced by local neurotrophin deprivation do not involve caspases. J Neurosci 20:1333–1341
Fischer LR, Culver DG, Davis AA, Tennant P, Wang M, Coleman M, Asress S, Adalbert R, Alexander GM, Glass JD (2005) The WldS gene modestly prolongs survival in the SOD1G93A fALS mouse. Neurobiol Dis 19:293–300
Gallagher E, Gao M, Liu YC, Karin M (2006) Activation of the E3 ubiquitin ligase Itch through a phosphorylation-induced conformational change. Proc Natl Acad Sci U S A 103:1717–1722
George EB, Glass JD, Griffin JW (1995) Axotomy-induced axonal degeneration is mediated by calcium influx through ion-specific channels. J Neurosci 15:6445–6452
Gerdts J, Sasaki Y, Vohra B, Marasa J, Milbrandt J (2011) Image-based screening identifies novel roles for IkappaB kinase and glycogen synthase kinase 3 in axonal degeneration. J Biol Chem 286:28011–28018
Gillingwater TH, Haley JE, Ribchester RR, Horsburgh K (2004) Neuroprotection after transient global cerebral ischemia in Wld(s) mutant mice. J Cereb Blood Flow Metab Off J Int Soc Cereb Blood Flow Metab 24:62–66
Goll DE, Thompson VF, Li H, Wei W, Cong J (2003) The calpain system. Physiol Rev 83:731–801
Grant RJ, Sellings LH, Crocker SJ, Melloni E, Park DS, Clarke PB (2009) Effects of calpain inhibition on dopaminergic markers and motor function following intrastriatal 6-hydroxydopamine administration in rats. Neuroscience 158:558–569
Grunblatt E, Mandel S, Youdim MB (2000) Neuroprotective strategies in Parkinson’s disease using the models of 6-hydroxydopamine and MPTP. Ann N Y Acad Sci 899:262–273
Haase G, Pettmann B, Raoul C, Henderson CE (2008) Signaling by death receptors in the nervous system. Curr Opin Neurobiol 18:284–291
Hasbani DM, O’Malley KL (2006) Wld(S) mice are protected against the Parkinsonian mimetic MPTP. Exp Neurol 202:93–99
Hoopfer ED, McLaughlin T, Watts RJ, Schuldiner O, O’Leary DD, Luo L (2006) Wlds protection distinguishes axon degeneration following injury from naturally occurring developmental pruning. Neuron 50:883–895
Hou ST, Jiang SX, Aylsworth A, Ferguson G, Slinn J, Hu H, Leung T, Kappler J, Kaibuchi K (2009) CaMKII phosphorylates collapsin response mediator protein 2 and modulates axonal damage during glutamate excitotoxicity. J Neurochem 111:870–881
Hoxhaj G, Najafov A, Toth R, Campbell DG, Prescott AR, MacKintosh C (2012) ZNRF2 is released from membranes by growth factors, and together with ZNRF1, regulates the Na+/K+ATPase. J Cell Sci 125:4662–4675
Ikegami K, Kato S, Koike T (2004) N-alpha-p-tosyl-L-lysine chloromethyl ketone (TLCK) suppresses neuritic degeneration caused by different experimental paradigms including in vitro Wallerian degeneration. Brain Res 1030:81–93
Kariya S, Mauricio R, Dai Y, Monani UR (2009) The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy. Neurosci Lett 449:246–251
Kim Y, Zhou P, Qian L, Chuang JZ, Lee J, Li C, Iadecola C, Nathan C, Ding A (2007) MyD88-5 links mitochondria, microtubules, and JNK3 in neurons and regulates neuronal survival. J Exp Med 204:2063–2074
Lewcock JW, Genoud N, Lettieri K, Pfaff SL (2007) The ubiquitin ligase Phr1 regulates axon outgrowth through modulation of microtubule dynamics. Neuron 56:604–620
Lin CW, Liu HY, Chen CY, Hsueh YP (2014) Neuronally-expressed Sarm1 regulates expression of inflammatory and antiviral cytokines in brains. Innate Immun 20:161–172
Liu X, Van Vleet T, Schnellmann RG (2004) The role of calpain in oncotic cell death. Annu Rev Pharmacol Toxicol 44:349–370
Mack TG, Reiner M, Beirowski B, Mi W, Emanuelli M, Wagner D, Thomson D, Gillingwater T, Court F, Conforti L, Fernando FS, Tarlton A, Andressen C, Addicks K, Magni G, Ribchester RR, Perry VH, Coleman MP (2001) Wallerian degeneration of injured axons and synapses is delayed by a Ube4b/Nmnat chimeric gene. Nat Neurosci 4:1199–1206
Meyer zu Horste G, Miesbach TA, Muller JI, Fledrich R, Stassart RM, Kieseier BC, Coleman MP, Sereda MW (2011) The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration. Neurobiol Dis 42:1–8
Mi W, Beirowski B, Gillingwater TH, Adalbert R, Wagner D, Grumme D, Osaka H, Conforti L, Arnhold S, Addicks K, Wada K, Ribchester RR, Coleman MP (2005) The slow Wallerian degeneration gene, WldS, inhibits axonal spheroid pathology in gracile axonal dystrophy mice. Brain 128:405–416
Neukomm LJ, Freeman MR (2014) Diverse cellular and molecular modes of axon degeneration. Trends Cell Biol 24:515–523
Nikolaev A, McLaughlin T, O’Leary DD, Tessier-Lavigne M (2009) APP binds DR6 to trigger axon pruning and neuron death via distinct caspases. Nature 457:981–989
Nishimura K, Takahashi J (2013) Therapeutic application of stem cell technology toward the treatment of Parkinson’s disease. Biol Pharm Bull 36:171–175
Nix P, Hisamoto N, Matsumoto K, Bastiani M (2011) Axon regeneration requires coordinate activation of p38 and JNK MAPK pathways. Proc Natl Acad Sci U S A 108:10738–10743
Osterloh JM et al (2012) dSarm/Sarm1 is required for activation of an injury-induced axon death pathway. Science 337:481–484
Raff MC, Whitmore AV, Finn JT (2002) Axonal self-destruction and neurodegeneration. Science 296:868–871
Rao MV, Mohan PS, Peterhoff CM, Yang DS, Schmidt SD, Stavrides PH, Campbell J, Chen Y, Jiang Y, Paskevich PA, Cataldo AM, Haroutunian V, Nixon RA (2008) Marked calpastatin (CAST) depletion in Alzheimer’s disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci 28:12241–12254
Rose FF Jr, Meehan PW, Coady TH, Garcia VB, Garcia ML, Lorson CL (2008) The Wallerian degeneration slow (Wld(s)) gene does not attenuate disease in a mouse model of spinal muscular atrophy. Biochem Biophys Res Commun 375:119–123
Ross CA, Akimov S (2014) Human induced pluripotent stem cells: potential for neurodegenerative diseases. Hum Mol Genet 2014 May 13. pii: ddu204. [Epub ahead of print]
Ryan KA, Pimplikar SW (2005) Activation of GSK-3 and phosphorylation of CRMP2 in transgenic mice expressing APP intracellular domain. J Cell Biol 171:327–335
Saitoh F, Araki T (2010) Proteasomal degradation of glutamine synthetase regulates schwann cell differentiation. J Neurosci 30:1204–1212
Sajadi A, Schneider BL, Aebischer P (2004) Wlds-mediated protection of dopaminergic fibers in an animal model of Parkinson disease. Curr Biol 14:326–330
Samsam M, Mi W, Wessig C, Zielasek J, Toyka KV, Coleman MP, Martini R (2003) The Wlds mutation delays robust loss of motor and sensory axons in a genetic model for myelin-related axonopathy. J Neurosci 23:2833–2839
Sandoe J, Eggan K (2013) Opportunities and challenges of pluripotent stem cell neurodegenerative disease models. Nat Neurosci 16:780–789
Sasaki Y, Araki T, Milbrandt J (2006) Stimulation of nicotinamide adenine dinucleotide biosynthetic pathways delays axonal degeneration after axotomy. J Neurosci 26:8484–8491
Sasaki Y, Vohra BP, Baloh RH, Milbrandt J (2009a) Transgenic mice expressing the Nmnat1 protein manifest robust delay in axonal degeneration in vivo. J Neurosci 29:6526–6534
Sasaki Y, Vohra BP, Lund FE, Milbrandt J (2009b) Nicotinamide mononucleotide adenylyl transferase-mediated axonal protection requires enzymatic activity but not increased levels of neuronal nicotinamide adenine dinucleotide. J Neurosci 29:5525–5535
Saxena S, Caroni P (2007) Mechanisms of axon degeneration: from development to disease. Prog Neurobiol 83:174–191
Schaefer AM, Hadwiger GD, Nonet ML (2000) rpm-1, a conserved neuronal gene that regulates targeting and synaptogenesis in C. elegans. Neuron 26:345–356
Schliebs R, Arendt T (2011) The cholinergic system in aging and neuronal degeneration. Behav Brain Res 221:555–563
Shen H, Hyrc KL, Goldberg MP (2013) Maintaining energy homeostasis is an essential component of Wld(S)-mediated axon protection. Neurobiol Dis 59:69–79
Takano J, Tomioka M, Tsubuki S, Higuchi M, Iwata N, Itohara S, Maki M, Saido TC (2005) Calpain mediates excitotoxic DNA fragmentation via mitochondrial pathways in adult brains: evidence from calpastatin mutant mice. J Biol Chem 280:16175–16184
Tonks NK (2006) Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 7:833–846
Tsuji O, Miura K, Fujiyoshi K, Momoshima S, Nakamura M, Okano H (2011) Cell therapy for spinal cord injury by neural stem/progenitor cells derived from iPS/ES cells. Neurotherapeutics 8:668–676
Ueda H, Fujita R (2004) Cell death mode switch from necrosis to apoptosis in brain. Biol Pharm Bull 27:950–955
Unsain N, Higgins JM, Parker KN, Johnstone AD, Barker PA (2013) XIAP regulates caspase activity in degenerating axons. Cell Rep 4:751–763
Vande Velde C, Garcia ML, Yin X, Trapp BD, Cleveland DW (2004) The neuroprotective factor Wlds does not attenuate mutant SOD1-mediated motor neuron disease. Neuromolecular Med 5:193–203
Vosler PS, Gao Y, Brennan CS, Yanagiya A, Gan Y, Cao G, Zhang F, Morley SJ, Sonenberg N, Bennett MV, Chen J (2011) Ischemia-induced calpain activation causes eukaryotic (translation) initiation factor 4G1 (eIF4GI) degradation, protein synthesis inhibition, and neuronal death. Proc Natl Acad Sci U S A 108:18102–18107
Wakatsuki S, Saitoh F, Araki T (2011) ZNRF1 promotes Wallerian degeneration by degrading AKT to induce GSK3B-dependent CRMP2 phosphorylation. Nat Cell Biol 13:1415–1423
Waller A (1851) Experiments on the section of the glosso-pharnyngeal and hypoglossal nerves of the frog, and observations of the alterlations produced thereby in the structures of their primitive fibres. Edinburgh Med Surg J 76:369–376
Wang MS, Davis AA, Culver DG, Glass JD (2002) WldS mice are resistant to paclitaxel (taxol) neuropathy. Ann Neurol 52:442–447
Wang J, Zhai Q, Chen Y, Lin E, Gu W, McBurney MW, He Z (2005) A local mechanism mediates NAD-dependent protection of axon degeneration. J Cell Biol 170:349–355
Wang JT, Medress ZA, Barres BA (2012) Axon degeneration: molecular mechanisms of a self-destruction pathway. J Cell Biol 196:7–18
Whitmore AV, Lindsten T, Raff MC, Thompson CB (2003) The proapoptotic proteins Bax and Bak are not involved in Wallerian degeneration. Cell Death Differ 10:260–261
Williamson R, van Aalten L, Mann DM, Platt B, Plattner F, Bedford L, Mayer J, Howlett D, Usardi A, Sutherland C, Cole AR (2011) CRMP2 hyperphosphorylation is characteristic of Alzheimer’s disease and not a feature common to other neurodegenerative diseases. J Alzheimers Dis JAD 27:615–625
Xiong X, Wang X, Ewanek R, Bhat P, Diantonio A, Collins CA (2010) Protein turnover of the Wallenda/DLK kinase regulates a retrograde response to axonal injury. J Cell Biol 191:211–223
Xiong X, Hao Y, Sun K, Li J, Li X, Mishra B, Soppina P, Wu C, Hume RI, Collins CA (2012) The Highwire ubiquitin ligase promotes axonal degeneration by tuning levels of Nmnat protein. PLoS Biol 10:e1001440
Yahata N, Yuasa S, Araki T (2009) Nicotinamide mononucleotide adenylyltransferase expression in mitochondrial matrix delays Wallerian degeneration. J Neurosci 29:6276–6284
Yang J, Weimer RM, Kallop D, Olsen O, Wu Z, Renier N, Uryu K, Tessier-Lavigne M (2013) Regulation of axon degeneration after injury and in development by the endogenous calpain inhibitor calpastatin. Neuron 80:1175–1189
Yiu G, He Z (2006) Glial inhibition of CNS axon regeneration. Nat Rev Neurosci 7:617–627
Zhai Q, Wang J, Kim A, Liu Q, Watts R, Hoopfer E, Mitchison T, Luo L, He Z (2003) Involvement of the ubiquitin-proteasome system in the early stages of wallerian degeneration. Neuron 39:217–225
Zhong Q, Gao W, Du F, Wang X (2005) Mule/ARF-BP1, a BH3-only E3 ubiquitin ligase, catalyzes the polyubiquitination of Mcl-1 and regulates apoptosis. Cell 121:1085–1095
Zhu SS, Ren Y, Zhang M, Cao JQ, Yang Q, Li XY, Bai H, Jiang L, Jiang Q, He ZG, Chen Q (2011) Wld(S) protects against peripheral neuropathy and retinopathy in an experimental model of diabetes in mice. Diabetologia 54:2440–2450
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Wakatsuki, S., Araki, T. (2015). Significance of Mechanism-Oriented Research Toward Neuronal Protection Therapy Against Neurodegenerative Disorders ~ ZNRF1 E3 Ubiquitin Ligase as a Critical Mediator for Wallerian Degeneration and Neuronal Apoptosis. In: Wada, K. (eds) Neurodegenerative Disorders as Systemic Diseases. Springer, Tokyo. https://doi.org/10.1007/978-4-431-54541-5_8
Download citation
DOI: https://doi.org/10.1007/978-4-431-54541-5_8
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-54540-8
Online ISBN: 978-4-431-54541-5
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)